PESG publishes report on Silexion Therapeutics: breakthrough RNAi technology in the fight against KRAS-driven cancers Page 1

Silexion Therapeutics (NASDAQ: SLXN) has emerged as an intriguing but under-the-radar player in precision oncology, focused on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ: MACA), Silexion represents an exciting opportunity in the rapidly growing field of targeted cancer treatments, particularly in addressing the challenges of pancreatic and potentially other KRAS-driven cancers.

Technology Deep Dive: LODER and SIL-204